ACSL4 and renal cell carcinoma: In addition, higher GPX4 expression is correlated with a higher IC50 value of sorafenib; however, higher ACSL4 expression corresponds to a lower IC50 value of sorafenib in RCC patients, indicating that these ferroptosis-related genes are closely related to drug sensitivity (Fig. 3D) [281–283].